MedTrace Logo

Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia

NCT02714790 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 281

Last updated 2016-03-23

No results posted yet for this study

Summary

Study purpose is to assess the prognostic role of Minimal Residual Disease (defined as medullary expression of WT1 gene), performed at Baseline and during treatment according to clinical practice. MRD results will be relate to treatment outcome and survival analysis variables (Overall Survival, Disease Free Survival, Cumulative Incidence of Relapse)

Conditions

Sponsors & Collaborators

  • A.O.U. Città della Salute e della Scienza

    lead OTHER

Principal Investigators

  • Ernesta Audisio, MD · AO Città della Salute e della Scienza di Torino

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-06-30
Completion
2015-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02714790 on ClinicalTrials.gov